BioCentury
ARTICLE | Clinical News

DMP 115 perfluorocarbon: Partner Yamanouchi Pharmaceutical Co. Ltd. began clinical testing

June 29, 1998 7:00 AM UTC

ImaRx Pharmaceutical Corp., Tucson, Ariz. Product: DMP 115 perfluorocarbon ultrasound contrast agent Indication: Cardiologic and radiologic imaging Status: Partner Yamanouchi Pharmaceutical Co. Ltd....